{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T12:10:02Z","timestamp":1750335002059,"version":"3.41.0"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2025,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This pilot phase II study evaluated the combination of lenvatinib, a multi\u2010kinase inhibitor, and eribulin, a microtubule inhibitor, in patients with advanced solid tumors, including breast carcinoma, lung carcinoma, and sarcoma. Tumor angiogenesis and resistance mechanisms to anti\u2010angiogenic therapies were primary motivations for combining these agents. The trial enrolled 29 patients, heavily pretreated with at least three prior lines of chemotherapy, and aimed to assess the efficacy and safety of the combination therapy. Overall response rate (ORR) was 24% with the highest responses observed in breast cancer (29%) and lung cancer (33%) patients. Median progression\u2010free survival (PFS) was 7.4\u2009months (95% CI 4.5, NA), and overall survival (OS) was 8.2\u2009months (95% CI 6.4 to 14.9). A significant improvement in both OS and PFS was found in vimentin\u2010negative patients, suggesting that vimentin expression may be a predictor of treatment response. The most common treatment\u2010related adverse events (TRAEs) were oral mucositis, fatigue, neutropenia, and nausea. Grade \u22653 TRAEs included neutropenia (34.5%), febrile neutropenia (17.2%), and hypertension (13.8%), with one fatal case of sepsis reported. While the study demonstrated the potential of lenvatinib and eribulin in advanced solid tumors, particularly breast and lung cancers, it also highlighted the need for further investigation into biomarkers like vimentin to predict therapeutic outcomes. The combination therapy was manageable in terms of safety and toxicity, with a predictable safety profile. These findings suggest that lenvatinib and eribulin represent a promising treatment strategy for advanced, heavily pretreated solid tumors, warranting further exploration in larger clinical studies.<\/jats:p>","DOI":"10.1002\/ijc.35446","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T13:57:16Z","timestamp":1744725436000},"page":"752-759","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pilot phase <scp>II<\/scp> study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors"],"prefix":"10.1002","volume":"157","author":[{"given":"Ranjit","family":"Banwait","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology Oncology UT Health San Antonio, Mays Cancer Center  San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Ko","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology Oncology UT Health San Antonio, Mays Cancer Center  San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Michalek","sequence":"additional","affiliation":[{"name":"Biostatistics Division, Department of Population Health Sciences UT Health San Antonio  San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Liu","sequence":"additional","affiliation":[{"name":"Biostatistics Division, Department of Population Health Sciences UT Health San Antonio  San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Lathrop","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology Oncology UT Health San Antonio, Mays Cancer Center  San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Bowhay\u2010Carnes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology Oncology UT Health San Antonio, Mays Cancer Center  San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Fotopoulos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology Oncology UT Health San Antonio, Mays Cancer Center  San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Sarantopoulos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology Oncology UT Health San Antonio, Mays Cancer Center  San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Elledge","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology Oncology UT Health San Antonio, Mays Cancer Center  San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"Taverna","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology Oncology UT Health San Antonio, Mays Cancer Center  San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Karnad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology Oncology UT Health San Antonio, Mays Cancer Center  San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalliopi P.","family":"Siziopikou","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Pathology Northwestern University, Robert H. Lurie Comprehensive Cancer Center  Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3313-8458","authenticated-orcid":false,"given":"Virginia","family":"Kaklamani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology Oncology UT Health San Antonio, Mays Cancer Center  San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197111182852108"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03351-7"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/35025215"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.8043"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100250"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5270"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12604"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0163"},{"issue":"17","key":"e_1_2_15_10_1","first-page":"6413","article-title":"Mechanisms associated with tumor vascular shut\u2010down induced by combretastatin A\u20104 phosphate: intravital microscopy and measurement of vascular permeability","volume":"61","author":"Tozer GM","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-04-0345"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12488"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60070-6"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01283-0"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx284"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100054"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.11506"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_205423"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4726"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.35446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T11:54:17Z","timestamp":1750334057000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.35446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8,15]]}},"alternative-id":["10.1002\/ijc.35446"],"URL":"https:\/\/doi.org\/10.1002\/ijc.35446","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"type":"print","value":"0020-7136"},{"type":"electronic","value":"1097-0215"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"2024-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}